Browse by Audience
Skip to content
Papers of the Week
Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis.
Abstract
At present no real-world studies are available on different dupilumab dosing regimens in controlled atopic dermatitis (AD). The aim of this study was to clinically evaluate a patient-centered dupilumab dosing regimen in patients with controlled AD and to relate this to serum drug levels and serum biomarkers.